V. N. Kovalenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
V. N. Kovalenko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Galina V. Shavkuta
Rostov State Medical University
2 shared publications - A. M. Inkin
Rostov State Medical University
1 shared publication - A.S. Zubkova1 shared publication
- Alexandra S. Badyan
Rostov State Medical University
1 shared publication - Eleonora V. Dudnikova
Rostov State Medical University
1 shared publication Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (4) , 8-16
Stroke in young patients: prevention and early diagnosis
This review is based on analysis of information sources on the status and development of primary health care (PHC) globally and in selected countries, as well as international evidence-based guidelines. The paper assesses the incidence of stroke, as well as its prevention and early diagnosis in young patients. A database of publications, regulatory documents, and online resources was used, using selected keywords and concepts related to PHC management. Priority was given to materials from the last decade related to stroke in young patients. The increasing incidence of stroke in young patients is a concerning public health issue. The mean age of stroke in young people is decreasing (from 18 years), necessitating effective methods for the prevention, detection, and treatment of this disease. The steady increase in ischemic stroke rates, disability-adjusted life years (DALYs), and disease prevalence requires targeted prevention programs. This will reduce the medical and social burden, reduce the pressure on the healthcare system and improve public health outcomes.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Primary Health Care (Russian Federation)
- Vol. 2 (4) , 8-16
Open AccessStroke in young patients: prevention and early diagnosis
This review is based on analysis of information sources on the status and development of primary health care (PHC) globally and in selected countries, as well as international evidence-based guidelines. The paper assesses the incidence of stroke, as well as its prevention and early diagnosis in young patients. A database of publications, regulatory documents, and online resources was used, using selected keywords and concepts related to PHC management. Priority was given to materials from the last decade related to stroke in young patients. The increasing incidence of stroke in young patients is a concerning public health issue. The mean age of stroke in young people is decreasing (from 18 years), necessitating effective methods for the prevention, detection, and treatment of this disease. The steady increase in ischemic stroke rates, disability-adjusted life years (DALYs), and disease prevalence requires targeted prevention programs. This will reduce the medical and social burden, reduce the pressure on the healthcare system and improve public health outcomes.
- 20 June 2025
- Published by PANORAMA Publishing House in Terapevt (General Physician)
- No. 6,p. 60-70
Non-alcoholic fatty liver disease, metabolic dysfunction and sarcopenia
The aging of the population is accompanied by an increase in the number of chronic diseases, including NAFLD, metabolic syndrome, diabetes mellitus, prediabe tes, and sarcopenia. Insulin resistance, chronic inflammation, and metabolic disorders are common pathogenetic mechanisms linking all of these diseases. Sarcopenia, char acterized by loss of muscle mass and function, exacerbates metabolic disorders and increases the risk of developing prediabetes into type 2 diabetes mellitus. It should be noted that the effect of sarcopenic obesity on the progression of glycemic status, as determined by fasting plasma glucose and glycated hemoglobin, may be more pro nounced than the effect of sarcopenia alone or obesity alone. In addition, patients with diabetes and sarcopenia have certain changes in the composition of muscle fibers, which requires an integrated approach to diagnosis, prevention, and treatment.
- 20 June 2025
- Published by PANORAMA Publishing House in Terapevt (General Physician)
- No. 6,p. 60-70
Non-alcoholic fatty liver disease, metabolic dysfunction and sarcopenia
The aging of the population is accompanied by an increase in the number of chronic diseases, including NAFLD, metabolic syndrome, diabetes mellitus, prediabe tes, and sarcopenia. Insulin resistance, chronic inflammation, and metabolic disorders are common pathogenetic mechanisms linking all of these diseases. Sarcopenia, char acterized by loss of muscle mass and function, exacerbates metabolic disorders and increases the risk of developing prediabetes into type 2 diabetes mellitus. It should be noted that the effect of sarcopenic obesity on the progression of glycemic status, as determined by fasting plasma glucose and glycated hemoglobin, may be more pro nounced than the effect of sarcopenia alone or obesity alone. In addition, patients with diabetes and sarcopenia have certain changes in the composition of muscle fibers, which requires an integrated approach to diagnosis, prevention, and treatment.
- Open Access
- 28 June 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (2) , 76-83
Multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome associated with COVID-19
With the emergence of the SARS-CoV-2 virus in December 2019, all countries around the world have implemented various strategies to prevent its spread and intensively search for effective treatments. Initially, severe cases of the disease were considered only in adults, but later information appeared on the severe course of the disease in children and adolescents. This condition, which occurs as part of the transferred COVID-19, is called multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome. The available data indicate that MVS is the result of an innate and adaptive immune response characterized by a cytokine storm and a delayed immunological response to SARS-CoV-2. Epidemiological, clinical, and immunological differences classify MVS as a distinct syndrome from Kawasaki disease (БК), including age range, and geographic and ethnic distribution of patients. It should be noted that new data from patients with MVS point to unique characteristics of the immunological response, as well as clinical similarities with other inflammatory syndromes, which can serve as a guide in the search for molecular mechanisms involved in MVS. This review presents an analysis of studies on this topic: features of pathogenesis, diagnosis, treatment methods, as well as further directions for studying the problem. The search for mechanisms for the development of MVS in children continues, and, in turn, medical alertness, timely diagnosis and treatment make it possible to achieve the best possible result for such patients.
- 28 June 2023
- Published by Rostov State Medical University in Medical Herald of the South of Russia
- Vol. 14 (2) , 76-83
Open AccessMultisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome associated with COVID-19
With the emergence of the SARS-CoV-2 virus in December 2019, all countries around the world have implemented various strategies to prevent its spread and intensively search for effective treatments. Initially, severe cases of the disease were considered only in adults, but later information appeared on the severe course of the disease in children and adolescents. This condition, which occurs as part of the transferred COVID-19, is called multisystem inflammatory syndrome (MIS) or Kawasaki-like syndrome. The available data indicate that MVS is the result of an innate and adaptive immune response characterized by a cytokine storm and a delayed immunological response to SARS-CoV-2. Epidemiological, clinical, and immunological differences classify MVS as a distinct syndrome from Kawasaki disease (БК), including age range, and geographic and ethnic distribution of patients. It should be noted that new data from patients with MVS point to unique characteristics of the immunological response, as well as clinical similarities with other inflammatory syndromes, which can serve as a guide in the search for molecular mechanisms involved in MVS. This review presents an analysis of studies on this topic: features of pathogenesis, diagnosis, treatment methods, as well as further directions for studying the problem. The search for mechanisms for the development of MVS in children continues, and, in turn, medical alertness, timely diagnosis and treatment make it possible to achieve the best possible result for such patients.